– Sairopa Presents First Clinical Data on ADU-1604 Compound at SITC 38th Annual Meeting –

ROTTERDAM, The Netherlands – October 27, 2023 – Sairopa B.V., a clinical-stage company that develops novel treatments for cancer by modulating the patient’s immune system, announced its poster presentation at the SITC 38th Annual Meeting taking place November 3-5, 2023 in San Diego, California. The presentation, taking the form of a poster, presents early clinical data with encouraging early safety signals on ADU-1604, Sairopa’s anti-CTLA-4 antibody. ADU-1604 is being studied in Phase 1 clinical trials in PD-1 relapse/refractory melanoma patients. Data obtained from the dose-escalation stage will be presented and will provide further specifics about the safety, efficacy of ADU-1604, as well as modulation of pharmacodynamic markers supporting its potential use in future clinical applications. sairopa.com

Poster information:

Title: ADU-1604, a novel CTLA-4 blocking antibody modulates pharmacodynamic markers in PD1 relapse/refractory melanoma patients
Saturday, November 4
Poster Hall Hours: 9:00 a.m. – 8:30 p.m. (Reception: 5:10 p.m. – 6:40 p.m.)
Onsite Location: Exhibit Halls A and B1 – San Diego Convention Center
Number: 770

About Sairopa

Sairopa B.V. is a clinical-stage company that develops novel treatments for cancer by modulating the patient’s immune system. In April 2021 Sairopa acquired, backed by Van Herk Investments, a portfolio of therapeutic antibodies from Chinook Therapeutics, Inc. ADU-1805, anti-SIRPalpha antibody (Voets et al., 2019) is being developed in solid tumors (Phase 1) under an option agreement with Exelixis. ADU-1604, anti-CTLA4 antibody is developed by Sairopa in Phase 1 in PD-1 relapse/refractory melanoma patients. Both antibodies were originally developed by BioNovion/Aduro Biotech Europe using the proprietary B-Select antibody platform that was also used to identify pembrolizumab (Keytruda™), BION-1301 and MK-5890 (Guelen et al., 2022). For more information about Sairopa, please visit www.sairopa.com.



Investors Contact:
Gurvinder Singh Chahal
Chief Business Officer 
+31 (0) 85 9026939

Media Contact:
Dharminder Singh Chahal
Managing Director
+31 (0) 85 9026939

# # #